Understanding and Reducing Your Risk for AMD
February is Age-Related Macular Degeneration Awareness Month. A serious degenerative eye disease that can cause irreversible vision loss or blindness if left untreated, AMD is the most common reason patients are referred
read more
Honoring the Life and Legacy of Texas Retina Co-founder Albert Vaiser, MD
It is with great sadness that Texas Retina announces the passing of one of its three founders, Albert Vaiser MD, on Saturday, February 1, 2025, after a brief illness. Dr. Vaiser had celebrated
read more
Dr. Wang Discussed CLARITY Clinical Trial Enrollment at Presentation in Miami
Robert Wang, MD, Texas Retina’s Director of Clinical Research for Plano, recently spoke about the CLARITY clinical trial at a meeting of retina specialists held in Miami, Florida. A global, multi-center Phase
read more
Understanding Your Insurance Coverage in the New Year: How Prior Authorizations Can Impact Retina Care
Health insurance policies and coverage vary greatly. As we start a new year, it is important to understand how your specific plan works and how that can affect your retina care. Referrals
read more
Dr. Abbey Discusses Latest Dry AMD Treatment Research on New Podcast Episode
While anti-VEGF injections are widely used to treat patients with wet age-related macular degeneration (AMD), there have been limited treatment options available for dry AMD other than AREDS vitamin formulations and lifestyle
read more
Office Closures for 1/10/2025
Due to the winter weather, the following Texas Retina offices are CLOSED today, January 10, 2025: Dallas North Athens Denton Grapevine Mansfield Sherman Wichita Falls If you have an appointment scheduled that
read more
Winter Weather Closures
Due to the winter weather, the following Texas Retina offices are CLOSED today, January 9, 2025: Dallas North Arlington Athens Frisco Denton Fort Worth Grapevine Plano Sherman Wichita Falls If you have
read more
Dr. Anand Participated in Research on New Gene Therapy Drug for X-linked Retinitis Pigmentosa Published in American Journal of Ophthalmology
The two-year results of the Phase I/II, multi-center HORIZON clinical trial of the new subretinal gene therapy drug AGTC-501 for X-linked retinitis pigmentosa were recently published in the American Journal of Ophthalmology.
read more
2025 New Year’s Resolutions for Your Eyes
As 2025 begins, it is the perfect time to commit to living a healthy lifestyle. Here are eight New Year’s resolutions to improve your eye health and protect your vision: 1. Schedule
read more
Happy New Year!
Happy New Year! Our offices will be closed on Wednesday, January 1, 2025. As another year comes to a close, we want to thank all of our patients, referring physicians, neighbors and
read more